Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA

Feb 15 2018

• By Derrick Gingery

FDAEntrance_1200x675

Related Content

FDA Ends ANDA 'Reviews' To Streamline Approval Process

Jan 04 2018

US FDA Looks To Proactively Update Old Generic Drug Labels Under Pilot

Jan 29 2018

Trump's Budget Surprise: FDA Gains 13% Increase

Feb 12 2018

At US Generic Association Annual Meeting, Worries About Sustainability

Feb 13 2018

FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan

Feb 13 2018

Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds

Oct 17 2011

ANDA Refuse-to-Receive Challenges Become More Common – And More Successful

Jul 20 2015

Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories

Aug 10 2015

FDA Flexible With Accelerated Approval Evidence, Analysis Finds

Sep 02 2013

Additional Topics

United States Generic Drugs Review Pathway Drug Review Regulation FDA BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window